Furthermore, JPMorgan has raised Vir Biotechnology's stock target to $14 from $10, following the presentation of initial clinical data for its in-house developed masked Tumor Cell Engagers (TCEs ...

SAN FRANCISCO, February 19, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the ...

The EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech's COVID-19 antibody VIR-7831, which could become the fourth drug of its type cleared for earl Two ...

Vir Biotechnology has a twelve month low of $6.56 and a twelve month high of $14.45. Several research firms recently weighed in on VIR. Barclays reduced their price objective on Vir Biotechnology ...

SAN FRANCISCO and LONDON, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced that the first patient was dosed last week in a ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on ...

Analyst Roanna Ruiz from Leerink Partners maintained a Buy rating on Vir Biotechnology (VIR – Research Report) and keeping the price target at $18.00. Discover outperforming stocks and invest ...

Dr Rajesh Gupta, vice president, global health portfolio and public-private partnerships at Vir Biotechnology, said: “COVID-19 reinforced the ever-present global threat of infectious diseases ...

Short interest in Vir Biotechnology Inc (NASDAQ:VIR) decreased during the last reporting period, falling from 7.86M to 7.64M. This put 9% of the company's publicly available shares short.